A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions

American Journal of Managed Care

Volumn 4, Issue 6 SUPPL., 1998, Pages 854-862

  Halpern, Michael T ^a,b,c   Palmer, Cynthia S ^a   Stephen Foster, C ^a   Pal, Ashish ^a   Battista, Carmelina ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; DICLOFENAC; DORZOLAMIDE; LOPIDINE; MANNITOL; METHAZOLAMIDE; MITOMYCIN; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; RIMEXOLONE; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CORNEA TRANSPLANTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; EPISCLERITIS; EYE INFLAMMATION; HEALTH CARE UTILIZATION; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; UVEITIS;

ANTI-INFLAMMATORY AGENTS; DRUG COSTS; EYE DISEASES; HEALTH CARE COSTS; INTRAOCULAR PRESSURE; MANAGED CARE PROGRAMS; PREDNISOLONE; PREGNADIENES; UNITED STATES;

EID: 0031904423     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Foster CS, Alter G, DeBarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996;122:171-182.
2. Assil KK, Massry G, Lehmann R, Fox K, Stewart R. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. / Cataract Refract Surg 1997;23:750-757.
3. Miettinen R. Incidence of uveitis in Northern Finland. Ada Ophthalmol (Copenh) 1977;55:252-260.
4. Tran VT, Auer C, Guex-Crosier Y, Rittet N, Herbort CP. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994-95;18:293-298.
5. Baarsma GS. The epidemiology and genetics of endogenous uveitis: A review. Curr Eye Res 1992;11(suppl):1-9.
6. Javitt JC, Kendix M, Tielsch JM, et al. Geographic variation in utilization of cataract surgery. Med Care 1995;33: 90-105.
7. US Bureau of the Census. Statistical Abstract of the United States: 1995. 115th ed. Washington, DC: US Bureau of the Census; 1995.
8. National Center for Health Statistics: 1987-1990 National Health Interview Surveys [database on CD-ROM]. CD-ROM Series 10. SETS Version 1.21. Washington, DC: US Government Printing Office; 1993.
9. Katz G), Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluorouacil in high-risk glaucoma filtering surgery. Ophthalmology 1995; 102:1263-1269.
10. Physicians GenRx. St. Louis, MO: Mosby-Year Book, Inc. 1995.
11. HealthCare. Consultants of America, Inc. 1996 Physician Fee and Coding Guide. Augusta, GA: HealthCare Consultants of America, Inc., 1996.